ClinicalTrials.gg

Program

Donepezil

Also written as “Donepezil Hydrochloride”, “E2020” and “Donepezil TDS”.

Its studies are mostly in Alzheimer Disease · Down Syndrome · Lewy Body Disease · Cognitive Dysfunction · Dementia, led by 14 companies.

Furthest: phase 4, since Sep 12, 200579 company-led studies, 1 open or runningNext primary completion: May 6, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisai391 open or runningphase 4since Sep 12, 2005Nov 9, 2004May 6, 2030phase 1 · NCT07768592
Pfizer70 open or runningphase 4since Sep 9, 2005Sep 8, 2005none ahead
Corium60 open or runningphase 1since Nov 13, 2016Nov 13, 2016none ahead
Merck50 open or runningphase 2since Feb 14, 2014Oct 21, 2008none ahead
Dr. Reddy's Laboratories40 open or runningphase 1since Jan 3, 2012Jan 3, 2012none ahead
Teva Pharmaceutical Industries40 open or runningphase 1since Dec 14, 2010Dec 14, 2010none ahead
AstraZeneca30 open or runningphase 1since Jul 9, 2008Jul 9, 2008none ahead
Icure Pharmaceutical30 open or runningphase 3since Jun 22, 2017May 15, 2013none ahead
GlaxoSmithKline20 open or runningphase 2since Jun 30, 2006Jun 30, 2006none ahead
Sun Pharmaceutical Industries20 open or runningphase 1since Jan 11, 2011Jan 11, 2011none ahead
AbbVie10 open or runningphase 2since Aug 27, 2015Aug 27, 2015none ahead
dongkook-pharmaceutical-co-ltd10 open or runningphase 1since Feb 18, 2016Feb 18, 2016none ahead
teikoku-pharma-usa-inc10 open or runningphase 2since Jun 5, 2009Jun 5, 2009none ahead
theranexus10 open or runningphase 1since Oct 2, 2018Oct 2, 2018none ahead

Also a collaborator on its studies: pt-equilab-international.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Nov 29, 2007.

  1. Aug 27, 2015AbbVie's first study: phase 2 study in Dementia of Alzheimer's TypeNew to AbbVieAbbVie · NCT02549196 · 28 enrolled · United States
  2. Jan 18, 2016Phase 4 study in Dementia Associated With Cerebrovascular DiseaseEisai · NCT02660983 · 302 enrolled · Korea, Republic of
  3. Feb 18, 2016dongkook-pharmaceutical-co-ltd's first study: phase 1 study in Alzheimer DiseaseNew to dongkook-pharmaceutical-co-ltddongkook-pharmaceutical-co-ltd · NCT02695004 · 44 enrolled · Korea, Republic of
  4. Nov 13, 2016Corium's first study: phase 1 study in Alzheimer DiseaseNew to CoriumCorium · NCT02968719 · 107 enrolled · United States
  5. Jun 22, 2017Phase 3 study in Alzheimer DiseaseIcure Pharmaceutical · NCT03197740 · 399 enrolled · Korea, Republic of
  6. Aug 21, 2017Phase 1 study in Alzheimer DiseaseCorium · NCT03259958 · 86 enrolled · United States
  7. Nov 3, 2017Phase 1 study in Skin IrritationCorium · NCT03397862 · 256 enrolled · United States
  8. Jan 31, 2018Phase 1 study in Alzheimer DiseaseCorium · NCT03432195 · 66 enrolled · United States
  9. Feb 13, 2018Phase 1 study in Alzheimer DiseaseCorium · NCT03438604 · 24 enrolled · United States
  10. Oct 2, 2018theranexus's first study: phase 1 study in Cognitive DysfunctionNew to theranexustheranexus · NCT03698695 · 152 enrolled · France
  11. Mar 11, 2020Phase 1 study in Alzheimer DiseaseMerck · NCT04308304 · 27 enrolled · United States
  12. Nov 1, 2020Phase 1 study in Healthy SubjectsCorium · NCT04617782 · 60 enrolled · United States
  13. Jan 26, 2021Phase 1 study in Alzheimer DiseaseMerck · NCT04730635 · 44 enrolled · United States, Australia
  14. Aug 12, 2026Phase 1 study in Alzheimer DiseaseEisai · NCT07768592 · 32 planned

Ahead

  1. May 6, 2030Primary completion: phase 1 study in Alzheimer DiseaseEisai · NCT07768592

TargetBeta

ACHE →read by rule
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule

Other programs on ACHE

ProgramCompanyFurthest phaseStudies
huperzine Arulewanbangde-pharmaceutical-group-co-ltdphase 47
benzgalantamine gluconaterulealpha-cognition-incphase 41
Z 338ruleZeria Pharmaceuticalphase 312

Studies

The newest 60 of 79 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07768592Alzheimer Disease1Not yet recruitingEisaiMay 6, 203032
NCT04730635Alzheimer Disease · United States, Australia1CompletedMerckJan 20, 202344
NCT04617782Healthy Subjects · United States1CompletedCoriumApr 5, 202160
NCT04308304Alzheimer Disease · United States1CompletedMerckMay 18, 202227
NCT03698695Cognitive Dysfunction · France1CompletedtheranexusOct 20, 2019152
NCT03438604Alzheimer Disease · United States1CompletedCoriumJun 19, 201824
NCT03432195Alzheimer Disease · United States1CompletedCoriumJun 28, 201866
NCT03397862Skin Irritation · United States1CompletedCoriumMar 8, 2018256
NCT03259958Alzheimer Disease · United States1CompletedCoriumMar 13, 201886
NCT03197740Alzheimer Disease · Korea, Republic of3CompletedIcure PharmaceuticalJul 3, 2020399
NCT02968719Alzheimer Disease · United States1CompletedCoriumJul 11, 2017107
NCT02695004Alzheimer Disease · Korea, Republic of1Completeddongkook-pharmaceutical-co-ltdMar 201744
NCT02660983Dementia Associated With Cerebrovascular Disease · Korea, Republic of4CompletedEisaiJul 13, 2018302
NCT02549196Dementia of Alzheimer's Type · United States2CompletedAbbVieSep 28, 201728
NCT02345213Lewy Body Disease · Japan4CompletedEisaiMay 15, 2017160
NCT02178124Alzheimer Disease · Korea, Republic of1CompletedIcure PharmaceuticalDec 201424
NCT02097056Alzheimer Disease · Korea, Republic of4CompletedEisaiMay 2015171
NCT02094053Down Syndrome · Japan2CompletedEisaiSep 16, 201636
NCT02064920Alzheimer Disease2CompletedMerckJul 13, 201636
NCT02051335Memory Disorders · United Kingdom1CompletedAstraZenecaMay 201427
NCT02055703Healthy Subjects · United States1CompletedEisaiApr 2014195
NCT01923558Healthy · Canada1CompletedDr. Reddy's LaboratoriesOct 201076
NCT01923259Healthy · Canada1CompletedDr. Reddy's LaboratoriesOct 201094
NCT01860625Alzheimer Disease · Korea, Republic of1CompletedIcure PharmaceuticalDec 201336
NCT01843556Healthy Elderly Male · Japan1CompletedEisaiApr 201348
NCT01539031Alzheimer Disease · Japan3CompletedEisaiJan 2015351
NCT01506752Healthy Adult · Japan1CompletedEisaiSep 201120
NCT01506739Healthy Adult · Japan1CompletedEisaiMay 201112
NCT01504516Healthy · India1CompletedDr. Reddy's LaboratoriesNov 200925
NCT01504503Healthy · India1CompletedDr. Reddy's LaboratoriesNov 200926
NCT01485185Neuralgia · United Kingdom1CompletedGlaxoSmithKlineJul 3, 201248
NCT01439243Healthy · Canada1CompletedTeva Pharmaceutical IndustriesJul 200726
NCT01439230Healthy · Canada1CompletedTeva Pharmaceutical IndustriesAug 200736
NCT01404169Alzheimer Disease · China3CompletedEisaiJul 2014260
NCT01278407Lewy Body Disease · Japan3CompletedEisaiMar 2013142
NCT01276353Alzheimer Disease · Japan2CompletedEisaiApr 201245
NCT01276080Healthy · United States1CompletedSun Pharmaceutical IndustriesNov 200936
NCT01276067Healthy · United States1CompletedSun Pharmaceutical IndustriesNov 200932
NCT01260948Healthy · United States1CompletedTeva Pharmaceutical IndustriesMay 200626
NCT01260922Healthy · United States1CompletedTeva Pharmaceutical IndustriesMay 200626
NCT01181310Dementia1CompletedMerckOct 200731
NCT01082965Alzheimer Disease · United States–TerminatedPfizerJul 201218
NCT01063556Kidney Failure, Chronic · Japan4CompletedEisaiMar 20106
NCT01024660Alzheimer Disease · Canada, Peru, Poland and moreEarly 1CompletedAstraZenecaJan 2011155
NCT00959881Alzheimer Disease · United States1CompletedPfizerNov 200947
NCT00916383Irritation/Irritant · United States2Completedteikoku-pharma-usa-incJun 200949
NCT00934375Cognitive Dysfunction · United States4CompletedEisaiSep 2007145
NCT01146509Migraine Disorders · United States2CompletedEisaiApr 200489
NCT00777608Alzheimer Disease1CompletedMerckOct 2009106
NCT00754052Down Syndrome · United States3TerminatedEisaiNov 20088
NCT00754013Down Syndrome · United States3TerminatedEisaiOct 20089
NCT00713765Alzheimer Disease · United Kingdom1TerminatedAstraZenecaDec 200833
NCT00688376Neoplasms · United States, Argentina, Australia and more3CompletedEisaiMay 26, 200972
NCT00675025Down Syndrome · United States2TerminatedEisaiNov 13, 2008117
NCT00630851Alzheimer Disease · Sweden3CompletedPfizer249
NCT00711204Alzheimer Disease · United States4WithdrawnEisaiJun 20090
NCT00598650Lewy Body Disease2CompletedEisaiMar 2011160
NCT00571064Mild to Severe Alzheimer's Disease · United States4CompletedEisaiDec 200897
NCT00570128Down Syndrome · United States2CompletedEisaiSep 5, 2008129
NCT00566501Alzheimer Disease · United States3CompletedEisaiApr 1, 2010915

How it is read

Names in the registry

  • “Donepezil”, 26 entries
  • “Donepezil Hydrochloride”, 14 entries
  • “E2020”, 7 entries
  • “Donepezil TDS”, 5 entries
  • “Donepezil hydrochloride”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.